| Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma JD Christie, N Appel, H Canter, JG Achi, NM Elliott, AL de Matos, L Franco, ... Molecular Therapy-Oncolytics 22, 539-554, 2021 | 26 | 2021 |
| T-independent response mediated by oncolytic tanapoxvirus recombinants expressing interleukin-2 and monocyte chemoattractant protein-1 suppresses human triple negative breast … YR Suryawanashi, T Zhang, HM Woyczesczyk, J Christie, E Byers, ... Medical Oncology 34 (6), 1-11, 2017 | 13 | 2017 |
| Autologous transplantation using donor leukocytes loaded ex vivo with oncolytic myxoma virus can eliminate residual multiple myeloma NY Villa, MM Rahman, J Mamola, J D’Isabella, E Goras, J Kilbourne, ... Molecular Therapy-Oncolytics 18, 171-188, 2020 | 12 | 2020 |
| Treat and repeat: oncolytic virus therapy for brain cancer JD Christie, EA Chiocca Nature Medicine 28 (8), 1540-1542, 2022 | 8 | 2022 |
| Systemic Delivery of mLIGHT-Armed Myxoma Virus Is Therapeutic for Later-Stage Syngeneic Murine Lung Metastatic Osteosarcoma JD Christie, N Appel, L Zhang, K Lowe, J Kilbourne, J Daggett-Vondras, ... Cancers 14 (2), 337, 2022 | 7 | 2022 |
| Methods of treating cancer with tnf expressing myxoma virus DG McFadden, J Christie, J Blattman, MM Rahman US Patent App. 17/259,849, 2021 | | 2021 |
| TNF-Superfamily Arming and Leukocyte Based Delivery of Oncolytic Myxoma Virus in a Syngeneic Murine Lung Metastasis Model JD Christie Arizona State University, 2021 | | 2021 |
| Characterizing unconventional T cells in the tumor microenvironment of metastatic osteosarcoma N Appel, J Christie, J Blattman The Journal of Immunology 202 (1 Supplement), 138.20-138.20, 2019 | | 2019 |
| The Oncolytic Potential of Tanapoxvirus to Treat Retinoblastoma JD Christie | | 2016 |
